R R

What Is Ocrevus?

Ocrevus is a prescription intravenous medication containing ocrelizumab, a CD20-directed monoclonal antibody. It treats relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults. Ocrevus is also approved for relapsing-remitting multiple sclerosis in children aged 10 years and older who weigh at least 25 kilograms. It targets certain immune cells involved in MS-related inflammation. Ocrevus is administered by healthcare professionals and is distinct from Ocrevus Zunovo, which is a subcutaneous formulation containing ocrelizumab and hyaluronidase.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Ocrevus?

Ocrevus is a prescription intravenous medication containing ocrelizumab, a CD20-directed monoclonal antibody. It treats relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adults. Ocrevus is also approved for relapsing-remitting multiple sclerosis in children aged 10 years and older who weigh at least 25 kilograms. It targets certain immune cells involved in MS-related inflammation. Ocrevus is administered by healthcare professionals and is distinct from Ocrevus Zunovo, which is a subcutaneous formulation containing ocrelizumab and hyaluronidase.

read more about ocrevus ...

Copy this HTML:

Copy HTML Copied!

How Does Ocrevus Work?

Ocrevus attaches to CD20 proteins on certain B cells, leading to their depletion. These cells contribute to immune responses involved in inflammation and damage to the central nervous system in multiple sclerosis. Reducing CD20-positive B cells helps decrease inflammatory disease activity and can slow certain measures of disability progression. Ocrevus is considered a disease-modifying therapy rather than a medication that immediately relieves individual MS symptoms. It does not cure multiple sclerosis or reverse established nerve injury.

Who Can Receive Ocrevus Treatment?

Ocrevus is approved for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Adults with primary progressive MS can also receive treatment. The intravenous product is approved for pediatric patients aged 10 years and older who weigh at least 25 kilograms and have relapsing-remitting MS. A neurologist considers MS subtype, age, weight, infection risks, immunoglobulin levels, and previous treatment before prescribing it.

How Are Ocrevus Infusions Given?

For adults, Ocrevus treatment typically begins with a 300 mg intravenous infusion followed by another 300 mg infusion two weeks later. Maintenance treatment generally consists of 600 mg every six months. Pediatric patients receive dosing based on body weight according to the current label. Corticosteroids and antihistamines are administered before infusions to reduce infusion-related reactions. Patients undergo hepatitis B screening and other recommended assessments before starting treatment. Healthcare professionals monitor patients during and after infusions.

What Are the Side Effects and Warnings of Ocrevus?

Ocrevus can cause infusion-related reactions, respiratory infections, and other infections. Serious concerns include hepatitis B reactivation, progressive multifocal leukoencephalopathy, reduced immunoglobulin levels, liver injury, and immune-mediated colitis. Some patients can experience severe allergic or infusion reactions requiring urgent treatment. Clinicians review vaccination history and monitor for infections and other complications. New neurological changes, persistent diarrhea, jaundice, or severe breathing problems should be evaluated promptly.

Common Questions About Ocrevus

Is Ocrevus a treatment for multiple sclerosis?

Yes. Ocrevus is a disease-modifying treatment approved for specified relapsing forms of MS and primary progressive MS. The approved population depends on age and disease type.

How often are Ocrevus infusions given?

After the initial two-dose treatment, adult maintenance infusions are generally given every six months. Pediatric dosing depends on body weight.

Can children receive Ocrevus?

Yes. Intravenous Ocrevus is approved for relapsing-remitting MS in patients aged 10 years and older who weigh at least 25 kilograms.

Is Ocrevus the same as Ocrevus Zunovo?

No. Both contain ocrelizumab, but Ocrevus is administered intravenously. Ocrevus Zunovo contains additional hyaluronidase and is injected beneath the skin using different dosing instructions.

References

DailyMed - OCREVUS (ocrelizumab) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9da42362-3bb5-4b83-b4bb-b59fd4e55f0d. Date Accessed October 22, 2026.

DailyMed - OCREVUS ZUNOVO (ocrelizumab and hyaluronidase) injection. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b216af61-99d0-42a3-afc2-b5bf86df1ec0. Date Accessed October 22, 2026.

Ocrelizumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548145/. Date Accessed October 22, 2026.

Ocrelizumab Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a617026.html. Date Accessed October 22, 2026.

Ocrevus. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus. Date Accessed October 22, 2026.